JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...
QIAGEN announced that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all ...
A federal public health agency on Tuesday released its final report on a community blood screening project conducted last year to detect genetic evidence of a rare blood cancer in Luzerne, Schuylkill ...
People living in Schuylkill, Carbon and Luzerne counties are taking advantage of an opportunity to have a sample of their blood tested to determine whether they have been exposed to whatever is ...
QIAGEN 's QGEN ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) received FDA approval for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs). In this cancer group, blood cells in ...
A federal agency is encouraging people living in Schuylkill, Carbon and Luzerne counties to have a sample of their blood tested to determine whether they have been exposed to whatever is causing an ...
December 11, 2006 (Orlando) — Clinicians have a new biological prognostic indicator that is more specific than the classic risk factors of older age and risk of thrombosis. Researchers ...
A federal public health agency on Tuesday released its final report on a community blood screening project conducted last year to detect genetic evidence of a rare blood cancer in Luzerne, Schuylkill ...
Due to the greater-than-expected response, the federal Agency for Toxic Substances and Disease Registry will schedule appointments for a second round of JAK2 screening through Friday. The second round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback